A Phase 1/2 trial (MEDIOLA) of durvalumab and olaparib in solid cancer enrolled 34 patients with germline BRCA1 and/or BRCA2 mutated HER2-negative and metastatic BC. Here, BRCA2 is linked to breast cancer.